Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity

Genes and Development

Volumn 31, Issue 12, 2017, Pages 1212-1227

  Zanca, Ciro ^a   Villa, Genaro R ^a,b,c   Benitez, Jorge A ^a   Thorne, Amy Haseley ^a   Koga, Tomoyuki ^a   D’Antonio, Matteo ^d   Ikegami, Shiro ^a   Ma, Jianhui ^a   Boyer, Antonia D ^a   Banisadr, Afsheen ^a   Jameson, Nathan M ^a   Parisian, Alison D ^a   Eliseeva, Olesja V ^e   Barnabe, Gabriela F ^a   Liu, Feng ^a,f   Wu, Sihan ^a   Yang, Huijun ^a   Wykosky, Jill ^a   Frazer, Kelly A ^d,g,h   Verkhusha, Vladislav V ⁱ   Isaguliants, Maria G ^e,j,k   Weiss, William A ^l   Gahman, Timothy C ^a   Shiau, Andrew K ^a   Chen, Clark C ^d   Mischel, Paul S ^a,d,m   Cavenee, Webster K ^a,d,m   Furnari, Frank B ^a,d,m   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY   (Russian Federation)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h RADY CHILDREN'S HOSPITAL   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j KAROLINSKA INSTITUTE   (Sweden)

^k RIGA STRADINS UNIVERSITY   (Latvia)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

EGFR; Glioblastoma; IL 6; NF B; Survivin; Tumor heterogeneity

Indexed keywords

1NA PP 1; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN PROTEIN 4; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LAPATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; BRD4 PROTEIN, MOUSE; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER RESISTANCE; CONTROLLED STUDY; CYTOKINE RELEASE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUNEL ASSAY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL COMMUNICATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PATHOPHYSIOLOGY;

ANIMALS; CELL COMMUNICATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTERLEUKIN-6; MICE; MICE, NUDE; MUTATION; NF-KAPPA B; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 85027005612     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.300079.117     Document Type: Article

References (55)

1. Alcantara Llaguno Sheila R, Wang Z, Sun D, Chen J, Xu J, Kim E, Hatanpaa Kimmo J, Raisanen Jack M, Burns Dennis K, Johnson Jane E, et al. 2015. Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell 28: 429-440.
2. Altieri DC. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
3. Archetti M, Ferraro DA, Christofori G. 2015. Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer. Proc Natl Acad Sci 112: 1833-1838.
4. Bent EH, Gilbert LA, Hemann MT. 2016. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev 30: 1811-1821.
5. Bhat Krishna PL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James Johanna D, Goodman Lindsey D, et al. 2013. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24: 331-346.
6. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu ILY, Carro MS, Dai F, Tagge MJ, et al. 2011. NFKBIA deletion in glioblastomas. N Engl J Med 364: 627-637.
7. Brennan Cameron W, Verhaak Roel GW, McKenna A, Campos B, Noushmehr H, Salama Sofie R, Zheng S, Chakravarty D, San-born JZ, Berman Samuel H, et al. 2013. The somatic genomic landscape of glioblastoma. Cell 155: 462-477.
8. Brown Jonathan D, Lin Charles Y, Duan Q, Griffin G, Federation AJ, Paranal Ronald M, Bair S, Newton G, Lichtman AH, Kung AL, et al. 2014. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 56: 219-231.
9. Cahill KE, Morshed RA, Yamini B. 2016. Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy. Neuro Oncol 18: 329-339.
10. Caiado F, Silva-Santos B, Norell H. 2016. Intra-tumour heteroge-neity—going beyond genetics. FEBS J 283: 2245-2258.
11. Chan KS, Wong CH, Huang YF, Li HY. 2010. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 1: e57.
12. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. 2011. The brain tumor microenvironment. Glia 59: 1169-1180.
13. Cloughesy TF, Cavenee WK, Mischel PS. 2014. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9: 1-25.
14. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JPY, Baldwin AS. 2008. Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK. Genes Dev 22: 1490-1500.
15. Diaz Jr LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. 2012. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540.
16. Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, Jassal B, Jupe S, Korninger F, McKay S, et al. 2016. The reactome pathway knowledgebase. Nucleic Acids Res 44: D481-D487.
17. Fan Q-W, Cheng Christine K, Gustafson WC, Charron E, Zipper P, Wong Robyn A, Chen J, Lau J, Knobbe-Thomsen C, Weller M, et al. 2013. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 24: 438-449.
18. Friedmann-Morvinski D, Narasimamurthy R, Xia Y, Myskiw C, Soda Y, Verma IM. 2016. Targeting NF-κB in glioblastoma: a therapeutic approach. Sci Adv 2: e1501292.
19. Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. 2015. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer 15: 302-310.
20. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. 2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807-811.
21. Hodge DR, Hurt EM, Farrar WL. 2005. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512.
22. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. 2007. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci 104: 12867-12872.
23. Huang PH, Xu AM, White FM. 2009. Oncogenic EGFR signaling networks in glioma. Sci Signal 2: pre6.
24. Iliopoulos D, Hirsch HA, Struhl K. 2009. An epigenetic switch involving NF-κB, Lin28, Let-7 microRNA, and IL-6 links inflammation to cell transformation. Cell 139: 693-706.
25. Inda M-d-M, Bonavia R, Mukasa A, Narita Y, Sah DWY, Vanden-berg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, et al. 2010. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24: 1731-1745.
26. Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes M-C, Puram SV, Scott AM, Lorimer IAJ, et al. 2016. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci 19: 798-806.
27. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et al. 2014. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343: 189-193.
28. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. 2016. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res 44: D457-D462.
29. Lee H-J, Zhuang G, Cao Y, Du P, Kim H-J, Settleman J. 2014. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26: 207-221.
30. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov Jill P, Tamayo P. 2015. The molecular signatures database hallmark gene set collection. Cell Syst 1: 417-425.
31. Liu F, Hon Gary C, Villa Genaro R, Turner Kristen M, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee Ah Y, et al. 2015. EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling. Mol Cell 60: 307-318.
32. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. 2016. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131: 803-820.
33. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
34. Mazor T, Pankov A, Johnson Brett E, Hong C, Hamilton Emily G, Bell Robert JA, Smirnov Ivan V, Reis Gerald F, Phillips Joanna J, Barnes Michael J, et al. 2015. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28: 307-317.
35. Mazor T, Pankov A, Song Jun S, Costello Joseph F. 2016. Intratumoral heterogeneity of the epigenome. Cancer Cell 29: 440-451.
36. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JHY, Chute DJ, et al. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024.
37. Minematsu T, Sonoda T, Hashimoto T, Iwai M, Oppeneer T, Felder L, Shirai N, Miyashita A, Usui T. 2012. Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats. Biopharm Drug Dispos 33: 160-169.
38. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et al. 2014. Targeted therapy resistance mediated by dynamic regulation of extra-chromosomal mutant EGFR DNA. Science 343: 72-76.
39. Park JH, Lemmon MA. 2012. Occupy EGFR. Cancer Discov 2: 398-400.
40. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Waki-moto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, et al. 2014. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344: 1396-1401.
41. Reardon DA, Wen PY, Mellinghoff IK. 2014. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol 16: p 7-13.
42. Scaltriti M, Baselga J. 2006. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272.
43. Shcherbakova DM, Verkhusha VV. 2013. Near-infrared fluorescent proteins for multicolor in vivo imaging. Nat Methods 10: 751-754.
44. Shi J, Vakoc Christopher R. 2014. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell 54: 728-736.
45. Stuhlmiller Timothy J, Miller Samantha M, Zawistowski Jon S, Nakamura K, Beltran Adriana S, Duncan James S, Angus Steven P, Collins Kyla AL, Granger Deborah A, Reuther Rachel A, et al. 2015. Inhibition of lapatinib-induced kinome repro- gramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep 11: 390-404.
46. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550.
48. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, et al. 2011. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 1: 524-538.
49. Tchirkov A, Khalil T, Chautard E, Mokhtari K, Veronese L, Irthum B, Vago P, Kemeny JL, Verrelle P. 2007. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 96: 474-476.
50. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
51. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiem-phu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, et al. 2012. Differential sensitivity of glioma- versus lung cancer- specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2: 458-471.
52. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, et al. 2009. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 2393-2404.
53. Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DIS, Zairis S, Abate F, Liu Z, Elliott O, Shin Y-J, et al. 2016. Clonal evolution of glioblastoma under therapy. Nat Genet 48: 768-776.
54. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, Van-denBerg SR, Thorne AH, Chen CC, Mischel PS, et al. 2015. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res 75: 394-404.
55. Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J, Nair S, Chen LF. 2014. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene 33: 2395-2404.